in this issue
People & Business :: Companies
Lonza Signs Manufacturing Deal with U.S. Pharma Firm
12:16 AM MDT | October 21, 2009 | Deepti Ramesh
Lonza says it has signed an agreement with Alnara Pharmaceuticals (Cambridge, MA), a company that develops and commercializes protein therapeutics for the treatment of metabolic diseases, to manufacture Alnara’s lead product liprotamase - an oral, pancreatic enzyme replacement therapy (PERT) for patients with pancreatic insufficiency. Lonza will provide microbial fermentation, process optimization, technical and regulatory support, under the terms of the deal, and all related production will be conducted in Lonza’s FDA registered facility at...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee